[go: up one dir, main page]

HUP9903825A2 - GABAB-receptor agonisták alkalmazása gyógyszerkészítmények előállítására, valamint a vegyületek szűrővizsgálatára szolgáló eljárás - Google Patents

GABAB-receptor agonisták alkalmazása gyógyszerkészítmények előállítására, valamint a vegyületek szűrővizsgálatára szolgáló eljárás

Info

Publication number
HUP9903825A2
HUP9903825A2 HU9903825A HUP9903825A HUP9903825A2 HU P9903825 A2 HUP9903825 A2 HU P9903825A2 HU 9903825 A HU9903825 A HU 9903825A HU P9903825 A HUP9903825 A HU P9903825A HU P9903825 A2 HUP9903825 A2 HU P9903825A2
Authority
HU
Hungary
Prior art keywords
gabab receptor
gabab
production
acid group
agonist
Prior art date
Application number
HU9903825A
Other languages
English (en)
Inventor
Paul L. R. Andrews
Anders Lehmann
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20403936&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP9903825(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Publication of HUP9903825A2 publication Critical patent/HUP9903825A2/hu
Publication of HUP9903825A3 publication Critical patent/HUP9903825A3/hu
Publication of HU224968B1 publication Critical patent/HU224968B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9426—GABA, i.e. gamma-amino-butyrate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A találmány tárgya egy GABAB receptor agonistának vagy gyógyá-szatilag elfogadható sójának vagy optikai izomerjének alkalmazása azalsó nyelőcsövi záróizom átmeneti ellazulásának gátlására és ezzelösszefüggésben a gyomor-nyelőcsövi visszafolyásos betegség ésgyermekek öklendezésének kezelésére szolgáló gyógyszerkészítményelőállításában. Az említett GABAB receptor agonista egy olyanszubsztituált amino-propionsav-származék, amelyben a savas végződésegy karboxi-csoport, foszfinsavcsoport, foszfonsavcsoport vagyszulfinsav-csoport. A legismertebb előnyös GABAB agonista a 4-amino-3-(4-klór-fenil)-vajsav (baklofen). A találmány tárgyát képezi továbbáaz ilyen célra alkalmazható vegyületek szűrővizsgálatára szolgálóeljárás is, amelynél egy sejttenyészetet transzfektálnak egy GABABreceptort kódoló nukleotidszekvenciával, hogy a GABAB receptorkifejeződjék a sejt felszínén; a vizsgált vegyületet érintkezésbehozzák az említett sejttel, és megvizsgálják, hogy a vegyület kötődik-e a GABAB receptorhoz és/vagy aktiválja-e azt. Ó
HU9903825A 1996-09-18 1997-09-15 Use of gabab receptor agonists for production of anti reflux pharmaceutical compositions HU224968B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9603408A SE9603408D0 (sv) 1996-09-18 1996-09-18 Medical use
PCT/SE1997/001555 WO1998011885A1 (en) 1996-09-18 1997-09-15 Reflux inhibitors

Publications (3)

Publication Number Publication Date
HUP9903825A2 true HUP9903825A2 (hu) 2001-05-28
HUP9903825A3 HUP9903825A3 (en) 2001-06-28
HU224968B1 HU224968B1 (en) 2006-04-28

Family

ID=20403936

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9903825A HU224968B1 (en) 1996-09-18 1997-09-15 Use of gabab receptor agonists for production of anti reflux pharmaceutical compositions

Country Status (34)

Country Link
US (2) US6117908A (hu)
EP (2) EP0936906B1 (hu)
JP (1) JP4098832B2 (hu)
KR (2) KR100553294B1 (hu)
CN (1) CN1117560C (hu)
AR (1) AR007747A1 (hu)
AT (2) ATE249212T1 (hu)
AU (1) AU714370B2 (hu)
BR (1) BR9711400A (hu)
CA (1) CA2265615C (hu)
CZ (1) CZ299997B6 (hu)
DE (2) DE69736445T2 (hu)
DK (2) DK1344524T3 (hu)
EE (1) EE03952B1 (hu)
ES (2) ES2206749T3 (hu)
HU (1) HU224968B1 (hu)
ID (1) ID19621A (hu)
IL (1) IL128961A (hu)
IS (2) IS2329B (hu)
MY (1) MY122020A (hu)
NO (1) NO326837B1 (hu)
NZ (2) NZ504244A (hu)
PL (1) PL190028B1 (hu)
PT (2) PT1344524E (hu)
RU (1) RU2199316C2 (hu)
SA (1) SA97180522B1 (hu)
SE (1) SE9603408D0 (hu)
SI (2) SI1344524T1 (hu)
SK (1) SK285744B6 (hu)
TR (1) TR199900591T2 (hu)
TW (1) TW548104B (hu)
UA (1) UA61081C2 (hu)
WO (1) WO1998011885A1 (hu)
ZA (1) ZA977969B (hu)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1094757C (zh) 1996-07-24 2002-11-27 沃尼尔·朗伯公司 用于治疗疼痛的异丁基γ－氨基丁酸及其衍生物
WO1999008670A1 (en) * 1997-08-20 1999-02-25 Guglietta, Antonio Gaba analogs to prevent and treat gastrointestinal damage
US6127418A (en) * 1997-08-20 2000-10-03 Warner-Lambert Company GABA analogs to prevent and treat gastrointestinal damage
EP0974351A3 (en) * 1998-04-24 2000-12-13 Jouveinal Medicament for preventing and treating gastrointestinal damage
US20080207755A1 (en) * 2000-05-31 2008-08-28 Pfizer Inc Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders
US7164034B2 (en) 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
SE9904507D0 (sv) * 1999-12-09 1999-12-09 Astra Ab New compounds
US7319095B2 (en) * 1999-12-09 2008-01-15 Astrazeneca Ab Use of GABAB receptor agonists
SE9904508D0 (sv) * 1999-12-09 1999-12-09 Astra Ab New compounds
TWI256314B (en) * 2000-02-09 2006-06-11 Mitsubishi Pharma Corp Preventive-therapeutical medicament for gastroesophageal reflux disease
EP1401423A4 (en) * 2001-05-29 2006-08-16 Depomed Dev Ltd METHOD FOR THE TREATMENT OF GASTROÖSOPHAGEAL REFLUX DISEASE AND NURSING ACID BREAKDOWN
SE0102058D0 (sv) * 2001-06-08 2001-06-08 Astrazeneca Ab New Salts II
SE0102057D0 (sv) * 2001-06-08 2001-06-08 Astrazeneca Ab New Salts I
AR033779A1 (es) * 2001-06-08 2004-01-07 Astrazeneca Ab Compuestos utiles en la enfermedad de reflujo
SE0102055D0 (sv) * 2001-06-08 2001-06-08 Astrazeneca Ab New Compounds
GB0209481D0 (en) * 2002-04-24 2002-06-05 Novartis Ag Organic compounds
SE0201939D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab New combination
SE0201943D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab New use
US7964609B2 (en) * 2002-06-20 2011-06-21 Astrazeneca Ab Use of mGluR5 antagonists for the treatment of gerd
SE0201940D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab New combination II
GB0226434D0 (en) * 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
NZ540591A (en) * 2002-12-13 2008-03-28 Warner Lambert Co Pregabalin derivatives for the treatment of fibromyalgia and other disorders
WO2005019163A2 (en) 2003-08-20 2005-03-03 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
CN101914040A (zh) * 2003-08-20 2010-12-15 什诺波特有限公司 酰氧基烃基氨基甲酸酯前药、合成方法及用途
EP2354120A1 (en) 2003-08-20 2011-08-10 XenoPort, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
AU2004272302A1 (en) * 2003-09-12 2005-03-24 Janssen Pharmaceutica N.V. Chimeric GABAb receptor
NZ546381A (en) * 2003-10-14 2010-01-29 Xenoport Inc Crystalline form of gamma-aminobutyric acid analog
GB0327186D0 (en) * 2003-11-21 2003-12-24 Novartis Ag Organic compounds
US20050220863A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
US20050220873A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
SE0401653D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab New compounds
WO2006050471A2 (en) * 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
US7494985B2 (en) * 2004-11-03 2009-02-24 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use
WO2006071186A1 (en) * 2004-12-27 2006-07-06 Astrazeneca Ab Use of gabab receptor agonists
BRPI0620464A2 (pt) 2005-12-23 2011-11-16 Astrazeneca Ab composto, composição farmacêutica, uso de um composto, e, método para o tratamento de uma doença
EP1966154A4 (en) * 2005-12-23 2011-01-26 Astrazeneca Ab IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
CA2631991A1 (en) * 2005-12-23 2007-06-28 Astrazeneca Ab Heterocyclic gaba-b modulators
KR20080090449A (ko) * 2005-12-23 2008-10-08 아스트라제네카 아베 Ｇｅｒｄ 및 ｉｂｓ의 치료를 위한 피라졸
EP1968946A4 (en) * 2005-12-23 2010-05-05 Astrazeneca Ab IMIDAZOLE AS MODULATORS OF THE GABA B RECEPTOR
US7585996B2 (en) * 2006-09-15 2009-09-08 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
ZA200904573B (en) 2006-12-22 2010-09-29 Ironwood Pharmaceuticals Inc Compositions comprising bile acid sequestrants for treating esophageal disorders
ES2365574T3 (es) * 2007-01-11 2011-10-07 Xenoport, Inc. Formas de dosificación oral para liberación continua de un profármaco de r-baclofeno y procedimientos de tratamiento.
KR20100015648A (ko) * 2007-04-18 2010-02-12 아스트라제네카 아베 양성 알로스테릭 ｇａｂａｂ 수용체 조절제 효과를 갖는 크산틴 화합물
US20090041806A1 (en) * 2007-06-15 2009-02-12 Xenoport, Inc. Use of prodrugs of gaba analogs, antispasticity agents, and prodrugs of gaba b receptor agonists for treating spasticity
US20100317626A1 (en) * 2007-07-25 2010-12-16 Astrazeneca Ab The Use Of (3-Amino-2-Fluoropropyl) Phosphinic Acid For Treatment Of NERD
WO2009061934A1 (en) * 2007-11-06 2009-05-14 Xenoport, Inc. Use of prodrugs of gaba b agonists for treating neuropathic and musculoskeletal pain
JP5291123B2 (ja) * 2008-01-25 2013-09-18 ゼノポート，インコーポレイティド （３ｓ）−アミノメチル−５−ヘキサン酸プロドラッグの結晶形態及びその使用
US7868043B2 (en) 2008-01-25 2011-01-11 Xenoport, Inc. Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
US7872046B2 (en) * 2008-01-25 2011-01-18 Xenoport, Inc. Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
US20100137442A2 (en) * 2008-02-01 2010-06-03 Xenoport, Inc. Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment
US8993639B2 (en) * 2008-03-20 2015-03-31 Burt Shulman Compound and method for treatment of gastroesophageal reflux
US7989641B2 (en) 2008-08-07 2011-08-02 Xenoport, Inc. Methods of synthesizing N-hydroxysuccinimidyl carbonates
WO2010017504A1 (en) * 2008-08-07 2010-02-11 Xenoport, Inc. Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
CA2753057C (en) 2009-03-03 2018-09-11 Xenoport, Inc. Sustained release oral dosage forms of an r-baclofen prodrug
US8344028B2 (en) * 2009-04-17 2013-01-01 Xenoport, Inc. Gamma-amino-butyric acid derivatives as GABAB receptor ligands
WO2011113904A1 (en) 2010-03-17 2011-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Medicaments for the prevention and treatment of a disease associated with retinal ganglion cell degeneration
WO2013023155A1 (en) 2011-08-11 2013-02-14 Xenoport, Inc. Anhydrous and hemihydrate crystalline forms of an (r)-baclofen prodrug, methods of synthesis and methods of use
WO2013180796A1 (en) 2012-06-01 2013-12-05 Lynn Health Science Institute, Inc. Methods for treating insomnia
WO2019162403A1 (en) * 2018-02-22 2019-08-29 Diamyd Medical Ab Gaba a receptor agonists for treatment of disorders influenced by dysfunction beta cells
TW202412754A (zh) * 2022-06-07 2024-04-01 瑞士商意梭凱普公司 應用於食道黏膜的包含逆流抑制劑的藥物傳遞系統

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987004077A1 (en) * 1986-01-03 1987-07-16 The University Of Melbourne Gastro-oesophageal reflux composition
NO882881L (no) * 1988-06-29 1990-01-02 Trond Nilsen Anordning for lengdekorrugering av metallplater.
GB8820266D0 (en) * 1988-08-26 1988-09-28 Smith Kline French Lab Compounds
WO1990009096A2 (en) * 1989-02-03 1990-08-23 Cambridge Neuroscience Research, Inc. Method of screening and classifying compounds
GB9117716D0 (en) * 1991-08-16 1991-10-02 Lynxvale Ltd Gaba derivatives and their therapeutic application
ES2174897T3 (es) * 1992-01-22 2002-11-16 Glaxo Group Ltd Uso medico de agonistas de beta-adrenoceptores atipicos.
GB9408064D0 (en) * 1994-04-22 1994-06-15 Merck Sharp & Dohme Nucleic acids
US5491134A (en) * 1994-09-16 1996-02-13 Bristol-Myers Squibb Company Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5656730A (en) * 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions

Also Published As

Publication number Publication date
US6117908A (en) 2000-09-12
BR9711400A (pt) 1999-08-17
TR199900591T2 (xx) 1999-07-21
WO1998011885A1 (en) 1998-03-26
DK0936906T3 (da) 2003-11-24
CN1237105A (zh) 1999-12-01
DE69736445T2 (de) 2007-03-15
IL128961A0 (en) 2000-02-17
KR20000036185A (ko) 2000-06-26
HU224968B1 (en) 2006-04-28
KR20050101237A (ko) 2005-10-20
KR100553294B1 (ko) 2006-02-22
ATE249212T1 (de) 2003-09-15
PT1344524E (pt) 2006-11-30
CN1117560C (zh) 2003-08-13
NO991287L (no) 1999-03-17
HK1022100A1 (en) 2000-07-28
AU714370B2 (en) 1999-12-23
JP4098832B2 (ja) 2008-06-11
NO326837B1 (no) 2009-02-23
ATE334700T1 (de) 2006-08-15
DE69736445D1 (de) 2006-09-14
SK285744B6 (sk) 2007-07-06
NO991287D0 (no) 1999-03-17
SK30599A3 (en) 2000-01-18
AU4406497A (en) 1998-04-14
PL332497A1 (en) 1999-09-13
EP0936906B1 (en) 2003-09-10
PT936906E (pt) 2003-12-31
DK1344524T3 (da) 2006-10-30
SA97180522B1 (ar) 2006-04-04
PL190028B1 (pl) 2005-10-31
JP2001501604A (ja) 2001-02-06
CZ299997B6 (cs) 2009-01-14
KR100568659B1 (ko) 2006-04-07
EE9900095A (et) 1999-10-15
EP0936906A1 (en) 1999-08-25
US6664069B1 (en) 2003-12-16
HUP9903825A3 (en) 2001-06-28
CA2265615A1 (en) 1998-03-26
HK1057004A1 (en) 2004-03-12
CZ93099A3 (cs) 1999-09-15
ES2206749T3 (es) 2004-05-16
MY122020A (en) 2006-03-31
SI1344524T1 (sl) 2006-12-31
EP1344524A1 (en) 2003-09-17
IS5001A (is) 1999-03-15
EP1344524B1 (en) 2006-08-02
AR007747A1 (es) 1999-11-10
NZ504244A (en) 2000-09-29
IS2538B (is) 2009-09-15
IS2329B (is) 2008-01-15
IL128961A (en) 2004-08-31
TW548104B (en) 2003-08-21
NZ334495A (en) 2000-09-29
SE9603408D0 (sv) 1996-09-18
DE69724809D1 (de) 2003-10-16
IS8623A (is) 2007-03-19
DE69724809T2 (de) 2004-07-15
ES2268227T3 (es) 2007-03-16
UA61081C2 (uk) 2003-11-17
SI0936906T1 (en) 2004-02-29
CA2265615C (en) 2007-01-30
EE03952B1 (et) 2003-02-17
ZA977969B (en) 1998-03-18
ID19621A (id) 1998-07-23
RU2199316C2 (ru) 2003-02-27

Similar Documents

Publication Publication Date Title
HUP9903825A2 (hu) GABAB-receptor agonisták alkalmazása gyógyszerkészítmények előállítására, valamint a vegyületek szűrővizsgálatára szolgáló eljárás
Sale et al. The substructure of isolated and in situ outer dynein arms of sea urchin sperm flagella.
RU99107969A (ru) Вещества, подавляющие рефлюкс
Thuong Nguyen et al. Choline acetyltransferase, acetylcholinesterase, and nicotinic acetylcholine receptors of human gingival and esophageal epithelia
CN105979959B (zh) 用于抑制磷酸盐转运的化合物和方法
Stasheff et al. NMDA antagonists differentiate epileptogenesis from seizure expression in an in vitro model
Yao et al. Pellicle precursor proteins: acidic proline-rich proteins, statherin, and histatins, and their crosslinking reaction by oral transglutaminase
Krnjevic Role of GABA in cerebral cortex
Sakata et al. Cav2. 3 (α1E) Ca2+ channel participates in the control of sperm function
WO2001082917A3 (en) Treatment of hypertriglyceridemia and other conditions using lxr modulators
Whishaw et al. Distinct forelimb and hind limb stepping impairments in unilateral dopamine-depleted rats: use of the rotorod as a method for the qualitative analysis of skilled walking
Xiao et al. Association of high HIF-1α levels in serous periodontitis with external root resorption by the NFATc1 pathway
Flavin et al. Enhanced aspartate release related to epilepsy in (EL) mice
Sasaki et al. Analysis of the development of normal foregut and tracheoesophageal fistula in an adriamycin rat model using three-dimensional image reconstruction
Aabakken et al. Visual analogue scales for endoscopic evaluation of nonsteroidal anti-inflammatory drug-induced mucosal damage in the stomach and duodenum
Choi et al. Activating of ATP-dependent K+ channels comprised of Kir 6.2 and SUR 2B by PGE2 through EP2 receptor in cultured interstitial cells of Cajal from murine small intestine
JP2013117382A (ja) 歯周病マーカー
Kuang et al. The enhancement of TXA2 receptors-mediated contractile response in intrarenal artery dysfunction in type 2 diabetic mice
Saban et al. Differential release of prostaglandins and leukotrienes by sensitized guinea pig urinary bladder layers upon antigen challenge
Kihara et al. GABA transaminase inhibitors enhance the release of endogenous GABA but decrease the release of β-alanine evoked by electrical stimulation of slices of the rat medulla oblongata
Ishizuka et al. Age-related changes in gallbladder contractility and cytoplasmic Ca2+ concentration in the guinea pig
WO1998053709A1 (es) Formulas de aminoacidos para personas de la tercera edad y procedimiento para el calculo de las mismas
Abudiak et al. The effect of fluoride slow-releasing devices on fluoride in plaque biofilms and saliva: a randomised controlled trial
WO2001090141A3 (en) Gb1c isoform and nucleotides
이파름 Peripheral Mechanisms of Nociception in Pathophysiological Conditions

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees